Genmab A/S (NASDAQ:GMAB) Downgraded to “Underperform” Rating by Sanford C. Bernstein

Sanford C. Bernstein cut shares of Genmab A/S (NASDAQ:GMAB) from a market perform rating to an underperform rating in a research note published on Tuesday morning, MarketBeat reports.

Other equities analysts have also recently issued reports about the company. Leerink Partners upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a research report on Thursday, February 13th. Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Truist Financial lowered their target price on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Tuesday, March 11th. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research note on Thursday, January 23rd. Finally, BNP Paribas raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.33.

Genmab A/S Stock Down 4.7 %

Genmab A/S stock opened at $18.66 on Tuesday. Genmab A/S has a 52 week low of $18.62 and a 52 week high of $30.50. The company’s 50 day moving average price is $20.81 and its two-hundred day moving average price is $21.73. The stock has a market cap of $12.35 billion, a P/E ratio of 10.72, a P/E/G ratio of 2.65 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, equities analysts anticipate that Genmab A/S will post 1.45 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Deep Track Capital LP purchased a new position in Genmab A/S during the fourth quarter valued at $41,740,000. Renaissance Technologies LLC grew its position in shares of Genmab A/S by 7.8% during the fourth quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company’s stock valued at $40,199,000 after purchasing an additional 139,722 shares in the last quarter. Two Sigma Investments LP increased its holdings in shares of Genmab A/S by 122.2% in the fourth quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company’s stock worth $35,612,000 after purchasing an additional 938,455 shares during the last quarter. Two Sigma Advisers LP lifted its position in shares of Genmab A/S by 168.8% in the fourth quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company’s stock worth $34,509,000 after buying an additional 1,038,400 shares in the last quarter. Finally, First Trust Advisors LP boosted its stake in Genmab A/S by 18.0% during the fourth quarter. First Trust Advisors LP now owns 1,644,288 shares of the company’s stock valued at $34,316,000 after buying an additional 251,241 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.